Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors

被引：11
|
作者：
Sobecki-Rausch, Janelle [1 ]
Barroilhet, Lisa [1 ]
机构：
[1] Univ Wisconsin, Sch Med & Publ Hlth, Div Gynecol Oncol, 600 Highland Ave, Madison, WI 53792 USA
来源：
CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2019年 / 20卷 / 11期
关键词：
Anti-PD-1; treatment; Endometrial cancer; Microsatellite instability; Mismatch repair deficiency; Pembrolizumab; IMMUNE CHECKPOINT INHIBITORS; LYNCH SYNDROME; OPEN-LABEL; PEMBROLIZUMAB; SAFETY;
D O I：
10.1007/s11864-019-0679-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Among gynecologic malignancies, mismatch repair-deficient endometrial cancers show the greatest response to anti-programmed cell death-1 (PD-1) antibodies, such as pembrolizumab. Routine immunohistochemical (IHC) and molecular testing should be performed on all endometrial cancers at the time of diagnosis in order to identify endometrial cancers with mismatch repair deficiency that may show improved response to anti-PD-1 therapy in the progressive or metastatic setting. Institutional effort to enroll patients in clinical trials investigating the use of immune checkpoint inhibitors in endometrial cancer should be prioritized.
引用
收藏
页数：10
相关论文
共 50 条
  • [41] Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma
    Xu Yang
    Baofeng Lian
    Nan Zhang
    Junyu Long
    Yiran Li
    Jingnan Xue
    Xiangqi Chen
    Yunchao Wang
    Yanyu Wang
    Ziyu Xun
    Mingjian Piao
    Chenpei Zhu
    Shanshan Wang
    Huishan Sun
    Zhijian Song
    Leilei Lu
    Xiaowei Dong
    Aodi Wang
    Wenjin Liu
    Jie Pan
    Xiaorong Hou
    Mei Guan
    Li Huo
    Jie Shi
    Haohai Zhang
    Jinxue Zhou
    Zhenhui Lu
    Yilei Mao
    Xinting Sang
    Liqun Wu
    Xiaobo Yang
    Kai Wang
    Haitao Zhao
    BMC Medicine, 22
  • [42] Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma
    Yang, Xu
    Lian, Baofeng
    Zhang, Nan
    Long, Junyu
    Li, Yiran
    Xue, Jingnan
    Chen, Xiangqi
    Wang, Yunchao
    Wang, Yanyu
    Xun, Ziyu
    Piao, Mingjian
    Zhu, Chenpei
    Wang, Shanshan
    Sun, Huishan
    Song, Zhijian
    Lu, Leilei
    Dong, Xiaowei
    Wang, Aodi
    Liu, Wenjin
    Pan, Jie
    Hou, Xiaorong
    Guan, Mei
    Huo, Li
    Shi, Jie
    Zhang, Haohai
    Zhou, Jinxue
    Lu, Zhenhui
    Mao, Yilei
    Sang, Xinting
    Wu, Liqun
    Yang, Xiaobo
    Wang, Kai
    Zhao, Haitao
    BMC MEDICINE, 2024, 22 (01)
  • [43] Predictors of innate resistance to pembrolizumab in patients with microsatellite instability-high endometrial cancer
    How, Jeffrey A.
    Dang, Minghao
    Ferri-Borgogno, Sammy
    Euscher, Elizabeth
    Yates, Melinda S.
    Peng, Weiyi
    Patel, Shrina D.
    Burks, Jared J.
    Vletic, Ivo
    Gomez, Javier
    Lu, Karen
    Mok, Samuel C.
    Wang, Linghua
    Jazaeri, Amir A.
    CANCER RESEARCH, 2022, 82 (12)
  • [44] Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
    Miyoshi, Yuka
    Ogawa, Osamu
    Oyama, Yu
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2016, 239 (02): : 155 - 158
  • [45] Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
    Liu, Gang
    Zhou, Wenxuan
    Li, Xiaoli
    Guo, Lijie
    He, Tingting
    Zhao, Juan
    Gong, Liansheng
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [46] Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacy
    Landre, Thierry
    Des Guetz, Gaetan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (04)
  • [47] Fulminant type1 diabetes mellitus with anti-programmed cell death-1 therapy
    Okamoto, Masahide
    Okamoto, Mitsuhiro
    Gotoh, Koro
    Masaki, Takayuki
    Ozeki, Yoshinori
    Ando, Hisae
    Anai, Manabu
    Sato, Asami
    Yoshida, Yuichi
    Ueda, So
    Kakuma, Tetsuya
    Shibata, Hirotaka
    JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (06) : 915 - 918
  • [48] Astragalus membranaceus-Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors
    Chang, Fu-Ling
    Tsai, Keng-Chang
    Lin, Tsai-Yu
    Yang, Tz-Wen
    Lo, Yan-Ni
    Chen, Wang-Chuan
    Chang, Jui-Hsien
    Lu, Mei-Kuang
    Chiou, Chun-Tang
    Chen, Po-Hung
    Yen, Yun
    Pan, Shiow-Lin
    Lee, Yu-Ching
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [49] Immunological features of a lung cancer patient achieving an objective response with anti-programmed death-1 blockade therapy
    Kamata, Toshiko
    Yoshida, Shigetoshi
    Takami, Mariko
    Ihara, Fumie
    Yoshizawa, Hiroko
    Toyoda, Takahide
    Takeshita, Yuichiro
    Nobuyama, Seiichi
    Kanetsuna, Yukiko
    Sato, Tetsuo
    Yoshino, Ichiro
    Motohashi, Shinichiro
    CANCER SCIENCE, 2020, 111 (01) : 288 - 296
  • [50] Galectin-3 and programmed cell death-1 ligand expression in colorectal microsatellite instability positive and negative tumors
    Bernal, M.
    Rodriguez, A. I.
    Saenz-Lopez, P.
    Moreno, A.
    Cabrera, T.
    Garrido, F.
    Ruiz-Cabello, F.
    TISSUE ANTIGENS, 2011, 77 (05): : 492 - 493
12345